REPARE THERAPEUTICS INC (RPTX) Fundamental Analysis & Valuation

NASDAQ:RPTX • US7602731025

2.65 USD
+0.02 (+0.76%)
At close: Jan 27, 2026
2.65 USD
0 (0%)
After Hours: 1/27/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This RPTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Taking everything into account, RPTX scores 3 out of 10 in our fundamental rating. RPTX was compared to 519 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RPTX as it has an excellent financial health rating, but there are worries on the profitability. RPTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. RPTX Profitability Analysis

1.1 Basic Checks

  • In the past year RPTX has reported negative net income.
  • RPTX had a negative operating cash flow in the past year.
  • In the past 5 years RPTX always reported negative net income.
  • RPTX had negative operating cash flow in 4 of the past 5 years.
RPTX Yearly Net Income VS EBIT VS OCF VS FCFRPTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

  • RPTX's Return On Assets of -56.96% is in line compared to the rest of the industry. RPTX outperforms 44.38% of its industry peers.
  • Looking at the Return On Equity, with a value of -62.71%, RPTX is in the better half of the industry, outperforming 60.38% of the companies in the same industry.
Industry RankSector Rank
ROA -56.96%
ROE -62.71%
ROIC N/A
ROA(3y)-30.96%
ROA(5y)-27.37%
ROE(3y)-36.88%
ROE(5y)-33.26%
ROIC(3y)N/A
ROIC(5y)N/A
RPTX Yearly ROA, ROE, ROICRPTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • RPTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RPTX Yearly Profit, Operating, Gross MarginsRPTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K -50K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. RPTX Health Analysis

2.1 Basic Checks

  • RPTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for RPTX has been increased compared to 1 year ago.
  • The number of shares outstanding for RPTX has been increased compared to 5 years ago.
  • There is no outstanding debt for RPTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RPTX Yearly Shares OutstandingRPTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RPTX Yearly Total Debt VS Total AssetsRPTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -0.11, we must say that RPTX is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -0.11, RPTX is in the better half of the industry, outperforming 60.19% of the companies in the same industry.
  • RPTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.11
ROIC/WACCN/A
WACC8.03%
RPTX Yearly LT Debt VS Equity VS FCFRPTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • RPTX has a Current Ratio of 10.71. This indicates that RPTX is financially healthy and has no problem in meeting its short term obligations.
  • RPTX's Current ratio of 10.71 is amongst the best of the industry. RPTX outperforms 84.38% of its industry peers.
  • A Quick Ratio of 10.71 indicates that RPTX has no problem at all paying its short term obligations.
  • RPTX has a Quick ratio of 10.71. This is amongst the best in the industry. RPTX outperforms 84.38% of its industry peers.
Industry RankSector Rank
Current Ratio 10.71
Quick Ratio 10.71
RPTX Yearly Current Assets VS Current LiabilitesRPTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. RPTX Growth Analysis

3.1 Past

  • RPTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.00%, which is quite good.
  • RPTX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -82.16%.
  • RPTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 91.62% yearly.
EPS 1Y (TTM)15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.94%
Revenue 1Y (TTM)-82.16%
Revenue growth 3Y91.62%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • RPTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.74% yearly.
  • Based on estimates for the next years, RPTX will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y-7.61%
EPS Next 2Y27.58%
EPS Next 3Y19.21%
EPS Next 5Y16.74%
Revenue Next Year-99.47%
Revenue Next 2Y-65.57%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
RPTX Yearly Revenue VS EstimatesRPTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
RPTX Yearly EPS VS EstimatesRPTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.5 -1 -1.5 -2 -2.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. RPTX Valuation Analysis

4.1 Price/Earnings Ratio

  • RPTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RPTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RPTX Price Earnings VS Forward Price EarningsRPTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RPTX Per share dataRPTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • RPTX's earnings are expected to grow with 19.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.58%
EPS Next 3Y19.21%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RPTX Dividend Analysis

5.1 Amount

  • No dividends for RPTX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RPTX Fundamentals: All Metrics, Ratios and Statistics

REPARE THERAPEUTICS INC

NASDAQ:RPTX (1/27/2026, 8:00:02 PM)

After market: 2.65 0 (0%)

2.65

+0.02 (+0.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)N/A
Inst Owners49.86%
Inst Owner Change-7.32%
Ins Owners0.35%
Ins Owner Change-1481.28%
Market Cap113.92M
Revenue(TTM)11.87M
Net Income(TTM)-72.20M
Analysts80
Price Target3.06 (15.47%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)78.35%
Min EPS beat(2)22.9%
Max EPS beat(2)133.81%
EPS beat(4)4
Avg EPS beat(4)44.79%
Min EPS beat(4)5.7%
Max EPS beat(4)133.81%
EPS beat(8)7
Avg EPS beat(8)235.55%
EPS beat(12)9
Avg EPS beat(12)166.28%
EPS beat(16)12
Avg EPS beat(16)143.18%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-83.41%
EPS NY rev (1m)0%
EPS NY rev (3m)-49.86%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-96.08%
Revenue NY rev (3m)-97.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.6
P/FCF N/A
P/OCF N/A
P/B 0.99
P/tB 0.99
EV/EBITDA N/A
EPS(TTM)-1.7
EYN/A
EPS(NY)-0.74
Fwd EYN/A
FCF(TTM)-1.63
FCFYN/A
OCF(TTM)-1.63
OCFYN/A
SpS0.28
BVpS2.68
TBVpS2.68
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -56.96%
ROE -62.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.96%
ROA(5y)-27.37%
ROE(3y)-36.88%
ROE(5y)-33.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.71
Quick Ratio 10.71
Altman-Z -0.11
F-Score3
WACC8.03%
ROIC/WACCN/A
Cap/Depr(3y)43.21%
Cap/Depr(5y)98.7%
Cap/Sales(3y)1.42%
Cap/Sales(5y)453.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.94%
EPS Next Y-7.61%
EPS Next 2Y27.58%
EPS Next 3Y19.21%
EPS Next 5Y16.74%
Revenue 1Y (TTM)-82.16%
Revenue growth 3Y91.62%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-99.47%
Revenue Next 2Y-65.57%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y13.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year14.95%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y45.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.47%
OCF growth 3YN/A
OCF growth 5YN/A

REPARE THERAPEUTICS INC / RPTX FAQ

What is the ChartMill fundamental rating of REPARE THERAPEUTICS INC (RPTX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to RPTX.


Can you provide the valuation status for REPARE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to REPARE THERAPEUTICS INC (RPTX). This can be considered as Overvalued.


What is the profitability of RPTX stock?

REPARE THERAPEUTICS INC (RPTX) has a profitability rating of 1 / 10.


What is the expected EPS growth for REPARE THERAPEUTICS INC (RPTX) stock?

The Earnings per Share (EPS) of REPARE THERAPEUTICS INC (RPTX) is expected to decline by -7.61% in the next year.